Literature DB >> 17653024

The metabolic syndrome is no better than its components.

C Iribarren1.   

Abstract

The usefulness of the metabolic syndrome is subject of debate. A central issue from the epidemiological perspective is whether the syndrome predicts cardiovascular disease above and beyond its individual components. In this paper, the current evidence regarding this matter is reviewed, and the conclusion of two recent studies is that there is no added predictive value of the syndrome when the individual components are in the model. Rather than perpetuate an arbitrary concept and create another disease entity, attention should be redirected to the individual components and, in particular, to the ''driving'' condition whose downstream consequences are serious in terms of morbidity and mortality: central or visceral obesity.

Entities:  

Mesh:

Year:  2007        PMID: 17653024

Source DB:  PubMed          Journal:  Minerva Cardioangiol        ISSN: 0026-4725            Impact factor:   1.347


  3 in total

1.  Impact of metabolic syndrome and its individual components on the presence and severity of angiographic coronary artery disease.

Authors:  Jong-Youn Kim; Hee-Sun Mun; Byoung Kwon Lee; Seong Bo Yoon; Eui-Young Choi; Pil-Ki Min; Young-Won Yoon; Bum-Kee Hong; Se-Joong Rim; Hyuck Moon Kwon
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

2.  Effect of Metabolic Syndrome Score, Metabolic Syndrome, and Its Individual Components on the Prevalence and Severity of Angiographic Coronary Artery Disease.

Authors:  Ming-Hui Gui; Yan Ling; Lin Liu; Jing-Jing Jiang; Xiao-Ying Li; Xin Gao
Journal:  Chin Med J (Engl)       Date:  2017-03-20       Impact factor: 2.628

3.  Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity according to the presence of diabetes mellitus: relation with inflammatory markers and adipokines.

Authors:  Jong-Youn Kim; Eui-Young Choi; Hee-Sun Mun; Pil-Ki Min; Young-Won Yoon; Byoung Kwon Lee; Bum-Kee Hong; Se-Joong Rim; Hyuck Moon Kwon
Journal:  Cardiovasc Diabetol       Date:  2013-10-02       Impact factor: 9.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.